Riskpilot← Back to searchSign inGet full accessAngelini Pharma Nordics AB
ABActiveOrg 5593260259Birger Jarlsgatan 6 DBusiness and other management consultancy activities · NACE 7020Est. 202116 employees
Revenue 2024
SEK 77,6M
+5% vs 2023
EBITDA margin
4.1%
+8% vs 2023
Equity ratio
52.0%
Financial strength
Net profit 2024
SEK 3,4M
+97% vs 2023
| Revenue | SEK 77,6M | +5% |
| EBITDA | SEK 3,2M | +8% |
| Net profit | SEK 3,4M | +97% |
| Total assets | SEK 51,8M | +10% |
| Equity | SEK 26,9M | +15% |
| Employees | 16 | — |
Legal name
Angelini Pharma Nordics AB
Org number
5593260259
Legal form
Aktiebolag
NACE code
7020 · Business and other management consultancy activities
Founded
5 juli 2021
Share capital
SEK 1 000 000
Employees
16 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas två i förening av ledamöterna Dessutom har verkställande direktören rätt att teckna firman beträffande löpande förvaltningsåtgärder
Company purpose
Bolaget ska bedriva handel och distribution av alla slag, särskilt läkemedelsproduktion, inklusive clearingkanaler, kommersiella agenter, import, export och direktleverans, produktion och registrering av läkemedelsprodukter, samt marknadsföringsaktiviteter relaterade till sådana produkter och handel med mediciner och läkemedelsprodukter samt därmed förenlig verksamhet.
Address
Birger Jarlsgatan 6 D
Email
nordics@angelinipharma.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenue | 71 838 | 73 703 | 77 613 |
| Staff expenses | — | — | — |
| EBITDA | 3 278 | 2 929 | 3 176 |
| Depreciation & amort. | −0 | −0 | −0 |
| EBIT | 3 278 | 2 929 | 3 176 |
| Net financials | 15 | 27 | 1 387 |
| Profit before tax | 2 455 | 2 370 | 4 623 |
| Tax | −651 | −633 | −1 198 |
| Net profit | 1 804 | 1 737 | 3 425 |
| Item | 2022 | 2023 | 2024 |
|---|---|---|---|
| Total assets | 59 099 | 47 012 | 51 792 |
| Equity | 21 773 | 23 512 | 26 931 |
| Long-term debt | 0 | 0 | 0 |
| Short-term debt | 36 326 | 21 500 | 22 857 |
| Total debt | 36 326 | 21 500 | 22 857 |
EBITDA margin
4.1%
This company
15.8%
Market median
-74% vs market
20222024
Equity ratio
52.0%
This company
38.2%
Market median
+36% vs market
20222024
Return on equity
12.7%
This company
18.4%
Market median
+31% vs market
20222024
Net profit margin
4.4%
This company
8.1%
Market median
-46% vs market
20222024
Asset turnover
1.50×
This company
1.12×
Market median
+34% vs market
20222024
Debt / equity
0.92×
This company
0.62×
Market median
+48% vs market
20222024
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
FA Chief Executive Officer | Chief Executive Officer | 2022 |
IM Chief Auditor | Chief Auditor | 2022 |
| Name | Role | Member since |
|---|---|---|
| Current (3) | ||
| Board of Directors | 2024 | |
| Board of Directors | 2026 | |
| Chairman | 2024 | |
| Former (4) | ||
| Deputy Board Member | 2021 – 2022 | |
| Chairman | 2022 – 2024 | |
| Board of Directors | 2021 – 2022 | |
| Board of Directors | 2022 – 2024 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Angelini Pharma Nordics AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Fräs Anna Kristina Andersson | Chief Executive Officer | 0 companies |
| Ida Maria Brandt | Chief Auditor | 0 companies |
| Ida Christina Svensson | Deputy Board Member | 0 companies |
| Luca Filipponi | Chairman | 0 companies |
| Azra Topaloglu | Board of Directors | 0 companies |
| Jetmir Daku | Board of Directors | 0 companies |
| Johan Fredrik Ståhl | Board of Directors | 0 companies |
| João Miguel Prazeres Faustino | Board of Directors | 0 companies |
| Erik Frans Lommerde | Chairman | 0 companies |